Epitope diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor reactivity

详细信息    查看全文

• 作者：Kosuke Ichikawa ; Hiroshi Kagamu ; Kenichi Koyama ; Takao Miyabayashi ; Jun Koshio ; Satoru Miura ; Satoshi Watanabe ; Hirohisa Yoshizawa ; Ichiei Narita
• 关键词：Tumor immunity ; Dendritic Cells ; IL-23 ; Th17
• 刊名：Vaccine
• 出版年：2012
• 出版时间：21 September, 2012
• 年：2012
• 卷：30
• 期：43
• 页码：6190-6197
• 全文大小：584 K

文摘

MHC class I-restricted peptide-based vaccination therapies have been conducted to treat cancer patients, because CD8⁺ CTL can efficiently induce apoptosis of tumor cells in an MHC class I-restricted epitope-specific manner. Interestingly, clinical responders are known to demonstrate reactivity to epitopes other than those used for vaccination; however, the mechanism underlying how antitumor T cells with diverse specificity are induced is unclear. In this study, we demonstrated that dendritic cells (DCs) that engulfed apoptotic tumor cells in the presence of non-tumor MHC class II-restricted epitope peptides, OVA_323-339, efficiently presented tumor-associated antigens upon effector-dominant CD4⁺ T cell balance against regulatory T cells (Treg) for the OVA_323-339 epitope. Th1 and Th17 induced tumor-associated antigens presentation of DC, while Th2 ameliorated tumor-antigen presentation for CD8⁺ T cells. Blocking experiments with anti-IL-23p19 antibody and anti-IL-23 receptor indicated that an autocrine mechanism of IL-23 likely mediated the diverted tumor-associated antigens presentation of DC. Tumor-associated antigens presentation of DC induced by OVA_323-339 epitope-specific CD4⁺ T cells resulted in facilitated antitumor immunity in both priming and effector phase in vivo. Notably, this immunotherapy did not require pretreatment to reduce Treg induced by tumor. This strategy may have clinical implications for designing effective antitumor immunotherapies.